EP2729194B1 - Antimicrobial parylene coatings and methods of depositing same - Google Patents

Antimicrobial parylene coatings and methods of depositing same Download PDF

Info

Publication number
EP2729194B1
EP2729194B1 EP12735756.4A EP12735756A EP2729194B1 EP 2729194 B1 EP2729194 B1 EP 2729194B1 EP 12735756 A EP12735756 A EP 12735756A EP 2729194 B1 EP2729194 B1 EP 2729194B1
Authority
EP
European Patent Office
Prior art keywords
parylene
coating
antimicrobial
antimicrobial agent
layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP12735756.4A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2729194A1 (en
Inventor
Rakesh Kumar
Yingfei Ke
Dustin ENGLAND
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Specialty Coating Systems Inc
Original Assignee
Specialty Coating Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Specialty Coating Systems Inc filed Critical Specialty Coating Systems Inc
Publication of EP2729194A1 publication Critical patent/EP2729194A1/en
Application granted granted Critical
Publication of EP2729194B1 publication Critical patent/EP2729194B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08—Materials for coatings
    • A61L29/085—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/202—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with halogen atoms, e.g. triclosan, povidone-iodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form

Definitions

  • EP1935355 Al discloses an enteral feeding tube comprising an antimicrobial coating that comprises a parylene coating.
  • Antimicrobial metal ions e.g. silver ions
  • the thickness of the parylene layer may be between 0.2 to 10 micron.
  • a method of forming an antimicrobial parylene coating may comprise immobilizing an antimicrobial agent on a parylene film through molecular attachment, interaction or covalent bonding via vapor-phase deposition, wherein the parylene film and the antimicrobial agent are deposited simultaneously on a substrate, or wherein the parylene film is deposited on a substrate prior to introduction of the antimicrobial agent, wherein the antimicrobial agent is octadecyldimethyl(3-trimethoxysilylpropyl)ammonium chloride, 4-chloro-3,5-dimethylphenol, or N-trimethoxysilylpropyl-N,N,N-trimethylammonium chloride.
  • a coating may comprise a parylene material and an antimicrobial agent immobilized on the parylene material through molecular entanglement or covalent bonding via vapor-phase deposition, wherein the antimicrobial agent is octadecyldimethyl(3-trimethoxysilylpropyl)ammonium chloride, 4-chloro-3,5-dimethylphenol, or N-trimethoxysilylpropyl-N,N,N-trimethylammonium chloride.
  • parylene coatings with antimicrobial properties may be provided.
  • methods may introduce materials with antimicrobial properties into parylene films during a parylene deposition process.
  • parylene coating surfaces may be rendered substantially antimicrobial by adding and/or copolymerizing an antimicrobial agent into a parylene coating.
  • Antimicrobial parylene films in accordance with one or more embodiments may be beneficial in circumstances where the performance properties of parylene films are desired in combination with an ability to control microbial growth on the film surface.
  • a parylene coating may be applied to a substrate.
  • the parylene coating may be a thin-film coating.
  • the coating may be continuous and substantially uniform across a substrate.
  • a parylene coating in a controlled thickness down to at least about several thousand angstroms may be achieved.
  • a parylene coating in a controlled thickness up to at least about several millimeters may also be achieved.
  • the thickness can generally be controlled to at least about plus or minus 10%.
  • the parylene coating may be conformal with respect to surfaces, edges and crevices of a substrate and may be substantially pinhole-free. Multi-layer penetration may be achieved.
  • a parylene coating may add minimal dimension or mass to critical, weight-sensitive components. Parylene coatings may be optically clear, or incorporated with an indicator compound, such as a fluorescent, to facilitate identification.
  • a parylene coating may be substantially biostable and biocompatible.
  • the coatings may comply with biological testing requirements for ISO-10993.
  • the coatings may comply with the biological testing requirements for USP Class VI plastics.
  • the coatings may promote proliferation of human cell types.
  • a parylene coating may exhibit barrier properties, such as may protect a substrate from fluids, moisture, chemicals and common gases. Protection from biofluids and biogases may be provided.
  • a parylene coating may exhibit a high dielectric strength and/or may impart dry-film lubricity to a substrate. Parylene coatings may protect against corrosion, discoloration and contaminant entrapment. Parylene coatings may serve as dielectric barriers.
  • a parylene coating may be flexible, deter surface tackiness, and reduce the coefficient of friction.
  • the parylene coating may have various coefficients of friction, for example, 0.15, 0.25 or 0.29 as measured by ASTM D 1894 for static observations.
  • a parylene coating may exhibit thermal and/or UV stability.
  • the substrate may be any material, device or component to which it may be desirable to apply a coating, such as a barrier or functional layer.
  • a parylene coating may be applied to virtually any surface material, including metals, elastomers, plastics, glasses, ceramics and papers. Parylene coatings may find applications in various industries including medical devices, electronics, automotive, military, aerospace, LEDs, and elastomers.
  • the substrate may be associated with electronics, printed circuit boards, printed circuit assemblies, sensors, detectors, LEDs, MEMS, capacitors, wafers, ferrite cores, fuel cells, digital displays, metal components.
  • the substrate may be a gasket or seal.
  • the substrate may be a medical device.
  • a parylene coating may be applied to an implantable or nonimplantable medical device.
  • a medical device such as but not limited to, a coronary stent, cerebral stent, cardiac assist device including pacemakers, electrosurgical tool, cochlear implant, ocular implant, mandrel, mold, catheter, elastomeric seal, needle, epidural probe or medical electronics may be coated with parylene.
  • Parylene coatings may also be used as release agents for molds and forming devices, such as wire mandrels. The parylene coating may provide an acceptable surface for tissue contact and may protect the medical device and associated components.
  • a parylene coating may function as a surface primer, such as on a drug-eluting stent where a drug-containing copolymer is applied to a parylene coated metal coronary stent for human implantation.
  • the parylene coating may enable integration of various drug and polymer combinations.
  • a parylene coating may be produced by vapor-phase deposition and polymerization of para-xylylene (poly(p-xylylene)) or its substituted derivatives.
  • the parylene coating may be made of any member of the generic parylene polymer series, or a variation thereof. Choice of a parylene polymer may be based on desired properties in view of an intended application.
  • a deposited parylene may be passive or reactive.
  • a deposited parylene may be halogenated.
  • parylene HT®, parylene N, parylene C or parylene D polymers commercially available from Specialty Coating Systems (Indianapolis, Indiana) as represented below may be deposited.
  • a parylene coating may be antimicrobial. Any parylene material may be deposited in conjunction with an antimicrobial agent to form an antimicrobial parylene coating.
  • antimicrobial liquids or solids with suitable vapor pressures and thermal stability may be introduced into a coating chamber during a parylene coating process.
  • an attached receptacle containing the antimicrobial material may be heated, allowing vaporized antimicrobial material to pass into the coating chamber.
  • the vaporized antimicrobial compound may be deposited on a substrate within the chamber simultaneously with a gaseous parylene monomer or in a layered approach. The amount and type of antimicrobial material used can be varied to suit a specific coating application.
  • one or more antimicrobial material(s) may be incorporated.
  • a parylene coating may be formed from a gaseous monomer without an intermediate liquid stage.
  • a parylene coating may be applied at ambient temperature with vacuum deposition equipment. The film may grow over time as parylene polymer deposition occurs at a molecular level.
  • a parylene coating may generally be applied in a room temperature vacuum chamber via a vapor deposition polymerization (VDP) process. Substrates to be coated may be placed into a coating chamber. A solid, granular dimer raw material may be heated under vacuum and vaporized into a dimeric gas. In some non-limiting embodiments, vaporization may be conducted at about 150°C and about 1.0 torr.
  • the gas may then be pyrolized to cleave the dimer to its monomeric form.
  • pyrolysis may be conducted at about 680°C and about 0.5torr.
  • the monomer gas may be deposited on a substrate as a polymer film in a deposition chamber at ambient temperature.
  • the film may be as thin or thick as desired based on an intended application and substantially transparent. In some embodiments, the thickness may range from hundreds of angstroms to several millimeters. In at least some embodiments, a typical thickness may be in the microns range.
  • antimicrobial compounds may be added to parylene films by various procedures as schematically illustrated in FIG. 1 .
  • parylene and antimicrobial molecules may be combined in the vapor-phase to produce an antimicrobial parylene coating.
  • a parylene film may be deposited on a substrate surface until a desired parylene film thickness is almost obtained.
  • heat sufficient to vaporize a desired antimicrobial compound may be applied to a receptacle containing the antimicrobial compound. This receptacle may be mounted to a coating chamber wall and may allow the passage of vaporized material into the coating chamber.
  • An antimicrobial compound such as but not limited to 4-Chloro-3,5-dimethylphenol, may be dissolved in a suitable carrier solvent to aid in distribution within the chamber.
  • the vaporized antimicrobial compound may enter the coating chamber and be deposited simultaneously with the gaseous parylene monomer on the growing parylene film surface.
  • the antimicrobial compound may be held in place through molecular entanglement with the parylene film near the film surface.
  • the antimicrobial agent(s) may be combined with parylene molecules through molecular attachment, interaction, and/or covalent bonding resulting in immobilization of the antimicrobial agent(s) on parylene coated surfaces.
  • deposition may be carried out in a PDS 2060PC parylene deposition system commercially available from Specialty Coating Systems.
  • Parylene dimer and the desired antimicrobial compound Once parylene dimer and the desired antimicrobial compound have been added to the PDS, the system may be placed under vacuum. Parylene dimer may be sublimated by heating at reduced pressure and passed through a furnace where the dimer may be cleaved by pyrolysis and allowed to pass into the deposition chamber in the form of a gaseous monomer. The monomer may strike the surface of the desired substrate and spontaneously polymerize into a continuous film on the substrate.
  • Antimicrobial compounds may be heated and introduced in gaseous form through a secondary port.
  • the antimicrobial compound is originally in solid form, such as 4-chloro-3,5-dimethylphenol, enough heat suitable to sublimate the compound, in some non-limiting embodiments between about 0°C and about 190°C, may be applied. If the desired antimicrobial compound is in neat liquid form or in solution, such as octadecyldimethyl(3-trimethoxysilylpropyl)ammonium chloride, the liquid may be heated at an appropriate rate based on the solvent in order to avoid rapid boiling. Standard parylene deposition process conditions, including temperature and pressure, may be implemented in accordance with one or more embodiments. Antimicrobial agents may be integrated in parylene deposition processes as discussed herein.
  • introduction of the gaseous antimicrobial compound can be performed concurrently with the introduction of gaseous parylene monomer or in an alternating fashion.
  • parylene may be deposited onto a substrate until a first thickness is obtained.
  • Antimicrobial agent may then be introduced and deposited concurrently with parylene until a second thickness is obtained.
  • a parylene topcoat may be applied to the antimicrobial layer.
  • a second parylene film deposition may be carried out to deposit a thin parylene film on top of the antimicrobial layer in order to control the rate of elution, if any, of the antimicrobial compound from the parylene film surface.
  • relative thickness between layers and overall coating thickness may vary depending on desired properties and intended application.
  • a layer of parylene about 0.5 to about 25 microns in thickness may be deposited prior to introduction of antimicrobial agent.
  • a layer including antimicrobial agent may be about 50 angstroms to about 5 microns in thickness.
  • an optional parylene topcoat may be about 0.1 micron to about 2 microns in thickness.
  • Components to be coated may require only minimal vacuum tolerance.
  • a substrate may be pretreated to promote optimal adhesion of parylene.
  • an A-174 silane treatment may be used.
  • Other adhesion promotion technologies may be used in conjunction with the deposition methods.
  • Substrate precleaning and cleanroom environments may also be implemented. Fixturing and masking techniques may be used to minimize contact points and avoid coating of areas to remain uncoated.
  • Octadecyldimethyl(3-trimethoxysilylpropyl)ammonium chloride was heated at an appropriate rate to achieve vaporization while avoiding rapid boiling.
  • the vaporized antimicrobial material striked the parylene film surface and became anchored to the parylene film through molecular entanglement, hydrogen bonding or covalent bonding depending on the functional groups present in the desired antimicrobial compound and/or on the parylene film surface.
  • the term “plurality” refers to two or more items or components.
  • the terms “comprising,” “including,” “carrying,” “having,” “containing,” and “involving,” whether in the written description or the claims and the like, are open-ended terms, i.e., to mean “including but not limited to.” Thus, the use of such terms is meant to encompass the items listed thereafter, and equivalents thereof, as well as additional items. Only the transitional phrases “consisting of” and “consisting essentially of,” are closed or semi-closed transitional phrases, respectively, with respect to the claims.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Materials For Medical Uses (AREA)
  • Paints Or Removers (AREA)
  • Application Of Or Painting With Fluid Materials (AREA)
  • Physical Vapour Deposition (AREA)
EP12735756.4A 2011-07-08 2012-07-06 Antimicrobial parylene coatings and methods of depositing same Active EP2729194B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161505762P 2011-07-08 2011-07-08
PCT/US2012/045728 WO2013009606A1 (en) 2011-07-08 2012-07-06 Antimicrobial parylene coatings and methods of depositing same

Publications (2)

Publication Number Publication Date
EP2729194A1 EP2729194A1 (en) 2014-05-14
EP2729194B1 true EP2729194B1 (en) 2021-06-02

Family

ID=46514839

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12735756.4A Active EP2729194B1 (en) 2011-07-08 2012-07-06 Antimicrobial parylene coatings and methods of depositing same

Country Status (4)

Country Link
US (1) US20130011456A1 (enrdf_load_stackoverflow)
EP (1) EP2729194B1 (enrdf_load_stackoverflow)
JP (1) JP2014524980A (enrdf_load_stackoverflow)
WO (1) WO2013009606A1 (enrdf_load_stackoverflow)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107708215B (zh) * 2012-06-12 2023-11-21 华为技术有限公司 载波资源配置方法、上行信息传输方法、基站及用户设备
US20150228916A1 (en) * 2014-01-29 2015-08-13 Massachusetts Institute Of Technology Bottom-up ultra-thin functional optoelectronic films and devices
US10327275B2 (en) * 2014-10-24 2019-06-18 Nokia Technologies Oy Network controlled and deployment based increased primary cell measurements
JP6703010B2 (ja) 2015-06-18 2020-06-03 カーディアック ペースメイカーズ， インコーポレイテッド 生体吸収性ポリマと抗菌剤とからなる植込型医療装置用ポリマカバー、およびその製造方法
JP2018526050A (ja) * 2015-07-11 2018-09-13 カーディアック ペースメイカーズ， インコーポレイテッド 抗菌性材料によるポリマーコーティングおよび製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07275262A (ja) * 1994-04-13 1995-10-24 Morita Mfg Co Ltd 医療用チューブおよびそれを備える診療装置
WO2002058577A1 (en) * 2000-11-13 2002-08-01 Wit Ip Corporation Hyperthermy treatment of the prostate and implantation of biodegradable urethral stent
US6586048B2 (en) * 2001-04-05 2003-07-01 Honeywell International Inc. Method for depositing a barrier coating on a polymeric substrate and composition comprising said barrier coating
JP3834655B2 (ja) * 2002-12-16 2006-10-18 国立大学法人広島大学 抗菌性材料、及びその製造方法
CN100557074C (zh) * 2003-04-25 2009-11-04 亚利桑那西格玛实验室公司 真空沉积功能化的多孔材料
PL1935355T3 (pl) * 2006-12-11 2016-03-31 Nutricia Nv Rurka do żywienia dojelitowego
EP2274985A4 (en) * 2008-05-09 2013-08-28 Univ Hiroshima METHOD FOR FIXING AN ANTIBACTERIAL ACTIVE AGENT AND ITEMS OBTAINED BY THIS METHOD
CN107006510B (zh) * 2008-12-25 2023-01-03 国立大学法人广岛大学 抗菌剂固定化方法及抗病毒剂固定化方法
EP2397574A4 (en) * 2009-02-16 2013-08-14 Mitsubishi Plastics Inc METHOD FOR PRODUCING A MULTILAYER GAS-REINFORCED FILM

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
EP2729194A1 (en) 2014-05-14
WO2013009606A1 (en) 2013-01-17
US20130011456A1 (en) 2013-01-10
JP2014524980A (ja) 2014-09-25

Similar Documents

Publication Publication Date Title
EP2729194B1 (en) Antimicrobial parylene coatings and methods of depositing same
US9210933B2 (en) Antimicrobial parylene coatings and methods of depositing same
Su et al. Mussel‐inspired, surface‐attachable initiator for grafting of antimicrobial and antifouling hydrogels
EP2318060B1 (de) Biokompatibilitätsschicht und beschichtete gegenstände
AU2009305471B2 (en) Medical device with controllably releasable antibacterial agent
Coad et al. Plasma polymerization for biomedical applications: A review
BRPI0902711A2 (pt) dispositivo médico com uma camada de ureiapoliuretano antibacteriana
US7815927B2 (en) Terpolymers for controlled release of bioactive agents from implantable medical devices
AU2016201153A1 (en) Packaging with active protection layer
US20050281858A1 (en) Devices, articles, coatings, and methods for controlled active agent release
Cristescu et al. Deposition of antibacterial of poly (1, 3-bis-(p-carboxyphenoxy propane)-co-(sebacic anhydride)) 20: 80/gentamicin sulfate composite coatings by MAPLE
US20060051522A1 (en) Method of pulsed laser assisted surface modification
BRPI0902955A2 (pt) dispersões de poliuretano não-iÈnicas, agentìferas aquosas
Zhou et al. Parylene coating hinders Candida albicans adhesion to silicone elastomers and denture bases resin
Al Nakib et al. Thermoplastic polyurethanes for biomedical application: A synthetic, mechanical, antibacterial, and cytotoxic study
NL2031339B1 (en) Antibacterial coating formed by copolymerization of chlorhexidine and catecholamine as well as preparation method and application thereof
US11884786B2 (en) Elastic parylene
Polívková et al. Cytotoxicity of Pd nanostructures supported on PEN: Influence of sterilization on Pd/PEN interface
RU2457001C2 (ru) Полиуретановый катетер с антимикробным покрытием, способ получения антимикробного покрытия на полиуретановых изделиях и способ изготовления полиуретановых катетеров с антимикробным покрытием
Caciandone-Cringureanu et al. Biofilms on Voice Prosthesis–Challenges and Therapeutic Insights
ES2720026B2 (es) Recubrimiento pro-biofilm, metodo para su produccion y sustrato recubierto por el mismo
KR20180101155A (ko) 4차 암모늄을 포함하는 항박테리아 고분자 필름, 이의 제조방법 및 용도
US20240325712A1 (en) Surface treatment for connectors
Vasilev et al. Platforms for controlled release of antibacterial agents facilitated by plasma polymerization
Khrisna et al. Antibacterial Analysis on Everolimus Grafted Biomaterial Surfaces using Polydopamine Intermediate Layer for Potential Use on Medical Devices

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131220

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20150413

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20201216

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1397820

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210615

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012075732

Country of ref document: DE

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210602

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210602

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210902

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210602

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20210602

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1397820

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210602

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210602

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210602

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210602

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210903

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210602

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210902

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210602

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210602

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210602

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210602

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210602

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211004

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210602

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210602

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210602

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012075732

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210602

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20210731

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210731

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210602

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210731

26N No opposition filed

Effective date: 20220303

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210706

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210602

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210602

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210706

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20120706

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210602

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230518

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210602

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210602

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210602

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240729

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240729

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240725

Year of fee payment: 13